Renal Artery Stenosis: A Common, Treatable Cause of Renal Failure?
- 1 February 2001
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 52 (1) , 421-442
Abstract
▪ Abstract Chronic azotemic renovascular disease is common in patients with atherosclerosis. Its prevalence appears to be increasing in the aging population. How often it is the primary cause of end-stage renal disease (ESRD) is not yet certain. Some studies suggest that 10%–40% of elderly hypertensive patients with newly documented ESRD and no demonstrable primary renal disease have significant renal artery stenosis (RAS). Atherosclerotic vascular occlusive disease of the renal arteries does progress, but current rates of progression and occlusion are lower than those reported a decade ago. Methods of identifying patients whose renal function is at true risk from vascular occlusive disease and determining who will benefit from intervention remain elusive. The presence of RAS in an azotemic patient can be assessed with noninvasive and risk-free radiologic techniques, including Duplex doppler velicometry and magnetic resonance angiography. Functional tests that predict the change in renal function after revascularization are not yet available. However, a renal length of greater than 7.5 cm in the absence of renal cysts and a short history of renal functional deterioration indicate a good prognosis. Patients with recent deterioration in renal function, those with bilateral renal artery stenosis or stenosis to a single functioning kidney, those with flash pulmonary edema, advanced chronic renal failure, or ESRD (who have much to gain), those with reversible azotemia during angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARB) therapy, and those whose conditions cannot be managed medically should be considered for revascularization. Results from recent controlled clinical trials of the response to percutaneous transluminal renal artery angioplasty (PTRA) and stenting indicate that improvement in blood pressure control or renal function is not a predictable outcome of renal revascularization. In azotemic groups, 25%–30% of patients achieve important recovery of renal function. Thus, significant progress has been made recently in determining whether RAS is a frequent, treatable cause of renal failure. The decision to recommend revascularization remains a difficult balance between the risks and expense of the procedure and the undoubted benefits that accrue if renal function is successfully stabilized.Keywords
This publication has 95 references indexed in Scilit:
- Outcomes of Atherosclerotic Renal Artery Stenosis Managed Without RevascularizationMayo Clinic Proceedings, 2000
- Role of Angiotensin and Oxidative Stress in Essential HypertensionHypertension, 1999
- Interactions of Transforming Growth Factor-β and Angiotensin II in Renal FibrosisHypertension, 1998
- Receptor-Mediated Intrarenal Angiotensin II Augmentation in Angiotensin II–Infused RatsHypertension, 1996
- Role of Nitric Oxide in Short-term and Prolonged Effects of Angiotensin II on Renal HemodynamicsHypertension, 1996
- Case Report: Brief Report: Acute Renal Failure after Losartan Treatment in a Patient with Bilateral Renal Artery StenosisBlood Pressure, 1996
- Early interstitial changes in hypertension-induced renal injury.Hypertension, 1993
- Renal nitric oxide and angiotensin II interaction in renovascular hypertension.Hypertension, 1993
- Effects of converting enzyme inhibition on split renal function in renovascular hypertension.Hypertension, 1986
- Captopril-Induced Functional Renal Insufficiency in Patients with Bilateral Renal-Artery Stenoses or Renal-Artery Stenosis in a Solitary KidneyNew England Journal of Medicine, 1983